Compare Msci Inc (MSCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TG Therapeutics Inc — how do they compare? Msci Inc trades at $565.48 (market cap $40.38B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Msci Inc is far larger — about 4.9× TG Therapeutics Inc's market cap, and Msci Inc pays a 1.48% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and TG Therapeutics Inc for 16 Days on average.
| MSCI | TGTX | |
|---|---|---|
Market Cap | $40.38B | $8.16B |
Volume | 414,140 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $643.83 | $59.06 |
52-Week Low | $511.84 | $26.94 |
Typical Hold Time | 82 Days | 16 Days |
Enterprise Value | $46.54B | $8.37B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.55, up 1.47% today, with a bullish technical signal and strong fundamentals including 40.73% net income margin and consistent revenue growth. Recent news highlights the completion of the First Street acquisition and upcoming Q3 2026 earnings call, reinforcing its strategic expansion in climate risk analytics.
The outlook is positive with a consensus price target of $701.71, though high valuation ratios and a recent earnings miss pose risks. Long-term growth is supported by recurring revenue streams and market leadership in index and analytics services.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
